Evidence map›Paper›PMID 42306077›Full record

ArticleLancet regional health. Americas2026

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Brandi N Reeves, Firas El Chaer, Lynda Foltz, Tsewang Tashi, Ghaith Abu-Zeinah, Albert Qin, Jennifer Lucas, Anna B Halpern, Dawn Maze, Hana Safah and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Brandi N ReevesDivision of Hematology, Department of Medicine, Blood Research Center, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Firas El ChaerDivision of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, VA, USA.
Lynda FoltzDivision of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Tsewang TashiHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Ghaith Abu-ZeinahDivision of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY 10021, USA.
Albert QinPharmaEssentia Corporation, Taipei, Taiwan.
Jennifer LucasMedical Oncology and Hematology, Marin Cancer Care, Greenbrae, CA, USA.
Anna B HalpernUniversity of Washington Medical Center and Fred Hutchinson Cancer Center, Seattle, WA, USA.
Dawn MazePrincess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Hana SafahOur Lady of the Lake Medical Center, Baton Rouge, LA, USA.
Casey L O'ConnellKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Swati GoelDepartment of Hematology and Oncology, Montefiore Einstein Comprehensive cancer center, Albert Einstein College of Medicine, Bronx, NY, USA.
Lindsay ReinDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Bruno FangAstera Cancer Care, East Brunswick, NJ, USA.
Joan HowDivision of Hematology and Oncology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Sunil BabuFort Wayne Medical Oncology & Hematology, Fort Wayne, IN, USA.
Zhuoyan LiGreater Baltimore Medical Center, Baltimore, MD, USA.
Sonia CerquozziDivision of Hematology and Hematologic Malignancies, University of Calgary, Alberta, Canada.
Stephen T OhDivision of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Anthony M HunterDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Nikolai PodoltsevMedicla Oncology and Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Pankit VachhaniO'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL, USA.
Julia M CunninghamDivision of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA.
Christopher HillisDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Prithviraj BoseDivision of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abdulraheem YacoubHematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas, MO, USA.
John MascarenhasTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Oleh ZagrijtschukPharmaEssentia USA, Burlington, MA, USA.
Henry CastroEverest Clinical Research, Markham, ON, Canada.
Ruben A MesaAtrium Health, Levine Cancer Institute, Cancer Programs, Wake Forest University School of Medicine, Charlotte, NC, USA.
Lucia MasarovaDivision of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ropeginterferon alfa-2b-njft (ropeg), a mono-PEGylated interferon-α, showed efficacy and safety in patients with hydroxyurea-intolerant/resistant essential thrombocythemia (ET) in the phase 3 SURPASS-ET largely conducted in Asia. Here we report the results from the EXCEED-ET study, which evaluated ropeg in both treatment-naïve and hydroxyurea pre-treated ET in North America. Methods: The single-arm, multicentre, phase 2b trial EXCEED-ET was conducted at 28 centers in the United States and Canada. Patients with ET enrolled were required to have a platelet count >450 × 10 Findings: Between January 17, 2023, and May 15, 2025, 106 patients were screened and 91 were enrolled. At baseline, participant median age was 57 years (range, 22-84) with 57/91 (62.6%) being female and 71/91 (78.0%) being White. Among 91 patients enrolled, durable modified ELN response rate was 60.2% (95% CI, 49.0-71.4). The median time to hematologic response was only 8.4 weeks (95% CI: 8.1-11.9). Splenomegaly and symptom improvement or non progression occurred in 90/91 (98.9%) and 71/91 (78.0%), respectively. Seven of 91 (7.7%) patients with palpable spleen at baseline and all had an improvement in disease-related signs. The rates of molecular response for driver mutations at Month 13 as defined by ELN2009 criteria were 35.0% (7/20) for patients with Interpretation: Ropeg showed efficacy and substantial molecular responses with good overall tolerability across a broad ET population. Funding: PharmaEssentia.

Indexed as

Essential thrombocythemiaNorthern AmericanPre-treatedRopeginterferon alfa-2b-njftTreatment-naïve

Identifiers

PMID42306077
PMCPMC13267617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.